GCTK Company Profile and Key Details

GlucoTrack, Inc. has 798.14 thousand shares outstanding. The public float is 639.90 thousand shares, elevated short interest at 1.57% of float. This equals 11.06 thousand shares. The short ratio is 0.01 days. Institutional investors hold 4.42% of the float. Insiders own 15.78%. SYCOFF DREW holds 138.00 thousand shares, John A. Ballantyne Revocable Living Trust dated 08/01/2017 has 59.26 thousand shares and BALLANTYNE JOHN has 59.26 thousand shares.

GlucoTrack, Inc. (NASDAQ:GCTK) closed at $2.03 USD, losing -$0.19 (-8.56%) from the previous close of $2.22. The stock is currently within 5% of its 52-week low $2.00 and $136.29. With a market capitalization of about $1.62 million, GlucoTrack, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.62). Key stats such as the average daily volume over the past year has been around 767.08 thousand shares, trading with heavier-than-usual volume. Headquartered in Rutherford, NJ, GlucoTrack, Inc. operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Erik Emerson, the company employs approximately 15 people and listed since April 25, 2013. GlucoTrack, Inc. is a medical device company that focuses on the design, development, and commercialization of novel technologies for people with diabetes.

GlucoTrack, Inc. (NASDAQ:GCTK) shares are flat -1.81% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows GlucoTrack, Inc. trading at a premium to the broader market with a P/E of -0.01. Our AI forecast model points to short-term weakness (-68.47% over two weeks), a medium-term fall (-24.63% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.

GlucoTrack, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $8.17. This means the shares are trading below this model’s fair value.

Our AI price prediction model suggests that GlucoTrack, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -68.47%, with price expected at $0.64 by October 05, 2026, within a range of $0.03 to $1.22 3-Month Outlook: Projected fall of -24.63%, reaching $1.53 by December 18, 2026, with a range of $0.00 to $6.33. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by September 21, 2027, within a range of $0.00 to $1.22 thousand.